Literature DB >> 7506689

Selection and design of high-affinity RNA ligands for HIV-1 Rev.

L Giver1, D P Bartel, M L Zapp, M R Green, A D Ellington.   

Abstract

We have used in vitro selection to isolate minimal, high-affinity RNA ligands for the Rev protein of HIV-1. Sequence analysis reveals that the tightest binding aptamers exhibit some similarity to a Rev-binding element (RBE) localized within the Rev-responsive element (RRE), but also contain novel sequence and structural motifs. A short helical stem and bulged nucleotides (nt) CUC ... UYGAG that have no counterpart in the wild-type (wt) element contribute to high-affinity binding. We have designed and synthesized a short (37 nt) RNA molecule that incorporates this motif; this RNA ligand has from three- to fivefold tighter binding than the full-length wt element, and up to 16-fold tighter than minimal wt RBEs. A guanosine:guanosine pairing that is postulated to occur in the wt element has been altered to other base pairings in the context of our optimized minimal element. RNAs that contain non-Watson-Crick base pairings, that can be modeled as isosteric to the wt G:G pair, bind Rev up to 160-fold tighter than elements that contain canonical Watson-Crick pairings or non-isosteric mismatches. These results support the hypothesis that Rev recognizes structural features associated with a non-Watson-Crick base pair.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506689     DOI: 10.1016/0378-1119(93)90246-y

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  11 in total

1.  Anti-Rex aptamers as mimics of the Rex-binding element.

Authors:  S Baskerville; M Zapp; A D Ellington
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Selections for constituting new RNA-protein interactions in catalytic RNP.

Authors:  Shota Atsumi; Yoshiya Ikawa; Hideaki Shiraishi; Tan Inoue
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

Review 3.  All you wanted to know about SELEX.

Authors:  S J Klug; M Famulok
Journal:  Mol Biol Rep       Date:  1994       Impact factor: 2.316

4.  A microarray-based method to perform nucleic acid selections.

Authors:  Olga Aminova; Matthew D Disney
Journal:  Methods Mol Biol       Date:  2010

5.  Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication.

Authors:  Timothy S Fisher; Pheroze Joshi; Vinayaka R Prasad
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  Recognition by viral and cellular DNA polymerases of nucleosides bearing bases with nonstandard hydrogen bonding patterns.

Authors:  J Horlacher; M Hottiger; V N Podust; U Hübscher; S A Benner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

7.  Characterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNA.

Authors:  Jessica E Wynn; Wenyu Zhang; Denis M Tebit; Laurie R Gray; Marie-Louise Hammarskjold; David Rekosh; Webster L Santos
Journal:  Bioorg Med Chem       Date:  2016-04-05       Impact factor: 3.641

8.  Targeting folded RNA: a branched peptide boronic acid that binds to a large surface area of HIV-1 RRE RNA.

Authors:  Wenyu Zhang; David I Bryson; Jason B Crumpton; Jessica Wynn; Webster L Santos
Journal:  Org Biomol Chem       Date:  2013-10-07       Impact factor: 3.876

9.  Identification of conserved RNA secondary structures at influenza B and C splice sites reveals similarities and differences between influenza A, B, and C.

Authors:  Lumbini I Dela-Moss; Walter N Moss; Douglas H Turner
Journal:  BMC Res Notes       Date:  2014-01-09

10.  Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection.

Authors:  William H Thiel; Thomas Bair; Andrew S Peek; Xiuying Liu; Justin Dassie; Katie R Stockdale; Mark A Behlke; Francis J Miller; Paloma H Giangrande
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.